Identification of novel deoxyribofuranosyl indole antimicrobial agents

Journal of Antibiotics

Volumn 65, Issue 2, 2012, Pages 53-57

  Paudel, Atmika ^a   Hamamoto, Hiroshi ^a   Kobayashi, Yoshihisa ^a   Yokoshima, Satoshi ^a   Fukuyama, Tohru ^a   Sekimizu, Kazuhisa ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

bactericidal; macromolecule synthesis; MRSA; novel antimicrobial; VRE

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; BACTERIAL RNA; CHLORAMPHENICOL; DAPTOMYCIN; DEOXYRIBOFURANOSYLINDOLE DERIVATIVE; FG 050204; FG 050223; FG 050227; INDOLE DERIVATIVE; NORFLOXACIN; PEPTIDOGLYCAN; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CANDIDA ALBICANS; CANDIDA TROPICALIS; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG IDENTIFICATION; DRUG SCREENING; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; FUNGI; GRAM-POSITIVE BACTERIA; HUMANS; INDOLES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); FUNGI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 84857704680     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2011.110     Document Type: Article

References (19)

1. Rammelkamp, C. H. & Maxon, T. Resistance of Staphylococcus aureus to the action of penicillin. Proc. Soc. Exp. Biol. Med. 51, 386-389 (1942).
2. Jevons, M. P. 'Celbenin' resistant Staphylococci. Br. Med. J. 14, 124-125 (1961).
3. Leclercq, R., Derlot, E., Duval, J. & Courvalin, P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. New Eng. J. Med. 319, 157-161 (1988).
4. Moellering, R. C. Jr. Vancomycin: A 50-year reassessment. Clin. Infect. Dis. 42, S3-S4 (2006). (Pubitemid 41832059)
5. Hiramatsu, K. et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40, 135-136 (1997). (Pubitemid 27341646)
6. Tsiodras, S. et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. The Lancet 358, 207-208 (2001). (Pubitemid 32718546)
7. Mangili, A., Bica, I., Snydman, D. R. & Hamer, D. H. Daptomycin-resistant, methicillinresistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40, 1058-1060 (2005). (Pubitemid 40418318)
8. Marty, F. M. et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. 44, 595-597 (2006). (Pubitemid 43224254)
9. Kobayashi, Y., Fujimoto, T. & Fukuyama, T. Stereocontrolled total synthesis of (+)- K252a. J. Am. Chem. Soc. 121, 6501-6502 (1999).
10. Endo, A. et al. Total Synthesis of Ecteinascidin 743. J. Am. Chem. Soc. 124, 6552-6554 (2002). (Pubitemid 34602645)
11. Sakaguchi, H., Tokuyama, H. & Fukuyama, T. Stereocontrolled total synthesis of ()- Kainic Acid. Org. Lett. 9, 1635-1638 (2007).
12. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically- Eighth Edition: Approved Standard M07-A, Clinical and Laboratory Standards Institute, Wayne, PA, (2009).
13. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved Standard M27-A, Clinical and Laboratory Standards Institute, Wayne, PA, (1997).
14. Maki, H., Miura, K. & Yamano, Y. Katanosin B and plusbacin A3, inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 1823-1827 (2001). (Pubitemid 32466355)
15. National Committe for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrtobial agents: Approved Guideline M-26-A, National Committe for Clinical Laboratory Standards, Wayne, PA, (1999).
16. Alder, J. & Eisenstein, B. The advance of bacterididal drugs in the treatment of infection. Curr. Infect. Dis. Reports 6, 251-253 (2004). (Pubitemid 39173558)
17. Stratton, C. W. Dead bugs don't mutate: Susceptibility issues in the emergence of bacterial resistance. Emerg. Infect. Dis. 9, 10-16 (2003). (Pubitemid 36110196)
18. Hobbs, J. K., Miller, K., O'Neill, A. J. & Chopra, I. Consequences of daptomycinmediated membrane damage in Staphylococcus aureus. J. Antimicrob. Chemother. 62, 1003-1008 (2008).
19. Ooi, N., Miller, K., Hobbs, J., Rhys-Williams, W., Love, W. & Chopra, I. XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. J. Antimicrob. Chemother. 64, 735-740 (2009).